Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Strange post by eagleeye on IV board.
http://www.investorvillage.com/smbd.asp?mb=971&pt=msg&mn=39719
Hard to know what he heard, let along put out in this post!
Thanks rfj. So is it time to accumulate some DYAX after yesterday's pullback?
Any links to best summaries of the company's prospects.
TIA!
<Prank on CAMH cc>
Dew, I don't think it was a prank. Some "Rich Rainy" fellow who said, "I'll be right with you in just a second, hold the phone....." But it was odd nonetheless!
<I reviewed the new institutional holders and it looked like a number of hedge funds were involved with the offering. >
Bio_pete, where do you see a list of new institutional holders? Do you have a link? Nice follow through today. tia
I surmise it was Mr MM gathering shares in the a.m. for Mr Institution to buy higher in the p.m.!
Amen!
Anyone watching the bid/ask spreads on RPRX in the last hour? Very wide ranges, and over 30 cents spread in one instance.
Reread my message again and you will see it is being played out as I type!
Bio_pete, I don't have an answer to your question.
I did talk to the CEO last week and he did say that during their road show tour that larger institutions were interested in the company, but not in the price (~12's) at that time (offering) as it had run up 100% in the past month.
So I would hope that these interested institutions would start to do some buying here in the 10's, as it is discounted 30% from the offering price.
Looks like we have punched through the 50 dma at the moment. I'd like to see the stock close back in the upper 10's today, if not near $11 with some interested buyers.
http://finance.yahoo.com/q/ta?s=RPRX&t=3m&l=on&z=m&q=b&p=m50,m100,m200,b&a=s....
Good luck!
OT: Unbelievable. Makes my first few experiences rafting down Blossom Bar section of the Rogue River (OR) seem like a walk through the park. That glider skier had to make high-speed split decisions on the fly! I kept thinking they were going to become ground beef on those rocks.
http://www.rivergeek.com/roguebb.html
The accumulation continues. 10.59, up 30 cents.
The Feb 16 options (10 strike calls) were trading at just 10 cents the other day and are probably asking 60 cents now. The could be a 10 fold winner (or more) in just 1 week for those lucky enough to have bought 2 days ago.
I agree. There are too few shares of RPRX in their float for more normal volatility. With around 8.5 mil shares this creates a lot volatility if a fund enters or exits. 400k shares is 5% of the float.
However, as you've said in other posts, the fundamentals of this company will drive the price higher regardless of the volatility. Makes for some fun swing trades if you can play that tune on the side.
I'm just glad my IDIX position countered this RPRX pullback! :)
Ok, I now found the link to 13G's. Aren't these 13G's pretty much standard reporting requirements of the SEC for statements of ownership?
"Statement of acquisition of beneficial ownership by individuals"
I agree we're in a downtrend after the secondary offering, however I don't see any correlation with the 13G reports.
What 13G's? I see RPRX 8-K's. I see someone is trying to sell 8000 shares at 11.34 No big buyer coming in at the moment. Loss of momentum and interest after the secondary.
OT: I saw these bar-headed geese for the first time this past week at Disneyworld's Animal theme park in Orlando, FL. I was probably one of a scarce few tourist's that was aware of their remarkable physiology care of your posts. Thanks!
Thanks for the link. Currently the site says that document isn't available at this time, and to check back later.
<Its worth noting (maybe) that there are 850 Feb. 12.5 puts outstanding.>
In other words, those long the stock and sold "puts" would like to see RPRX close at/over 12.5 by next Friday, correct?
thanks!
BSR site........just go here.
http://www.biotechmonthly.com/latest-issues.htm
You are welcome!!
marthambles, could this price decline also be related to RPRX's Feb 12.5 strike options which expire on Feb 16?
The stock seems to want to hover around $12.5 region today.
Otherwise, the stock is back to the low to mid $12's where it was after the breakout news from late December.
tia,
Spartex
Repros Therapeutics Announces Completion of Public Offering of Common Stock
Monday February 5, 1:30 pm ET
THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics Inc. (Nasdaq:RPRX - News) today announced the completion of a public offering of 2,610,000 shares of its common stock at a public offering price of $13.75 per share. The net proceeds to the company from the sale of shares of its common stock in this offering were approximately $33.0 million. CIBC World Markets Corp. acted as sole book-running manager in this offering. Punk, Ziegel & Company acted as co-lead manager. ThinkEquity Partners LLC acted as co-manager.
A registration statement relating to the shares has been declared effective by the Securities and Exchange Commission. Sales of shares pursuant to this offering may be made only by means of the final prospectus supplement and related prospectus, copies of which can be obtained from CIBC World Markets Corp. by email at useprospectus@us.cibc.com, by fax at 212-667-6303, or by mail at CIBC World Markets Corp., Attn: USE Prospectus Department, 425 Lexington Ave, 5th floor. NY, NY 10017. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
Contact:
Repros Therapeutics Inc., The Woodlands
Joseph S. Podolski, 281-719-3447
http://biz.yahoo.com/bw/070205/20070205006045.html?.v=1
Please define "a major hurting" for me.
thanks.
AstraZeneca Licenses Regeneron's VelocImmune(R) Technology for Discovering Human Monoclonal Antibodies
Monday February 5, 5:30 am ET
AstraZeneca Is First Licensee of Novel VelocImmune Technology
License Fees Total up to $120 Million Over Six Years
TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN - News) announced today it has entered into a non-exclusive license agreement that will allow AstraZeneca (LSE: AZN, NYSE: AZN) to utilize Regeneron's VelocImmune® technology in its internal research programs to discover human monoclonal antibodies. AstraZeneca will conduct the work at Cambridge Antibody Technology (CAT) in the UK as part of its recently stated aim of building a biopharmaceutical capability.
AstraZeneca will pay $20 million upfront and will make up to five additional annual payments of $20 million, subject to the ability to terminate the agreement after making the first three additional payments. Upon commercialization of any antibody products discovered utilizing VelocImmune, AstraZeneca will pay to Regeneron a mid-single-digit royalty on product sales.
"VelocImmune is the centerpiece of Regeneron's suite of technologies for the discovery and development of fully human antibodies," said George D. Yancopoulos, M.D., Ph.D., President of Regeneron Research Laboratories and Regeneron's Chief Scientific Officer. "We are pleased that AstraZeneca, a company with a clear strategic commitment to developing therapeutic antibodies, has selected the VelocImmune platform for its internal development program."
"AstraZeneca is committed to becoming a leader in the area of biologicals and VelocImmune is an important part of our strategy to succeed in this field," said Jan Lundberg, Ph.D., Executive VP Global Discovery Research.
Alex Duncan, Ph.D., CAT's SVP Drug Discovery, commented, "This combination of CAT's display technologies and the VelocImmune platform will provide enormous potential for creating antibody therapeutics."
VelocImmune and Regeneron's Discovery Platforms
Regeneron's VelocImmune technology offers the potential to increase dramatically the speed and efficiency of discovering fully-human, therapeutic monoclonal antibodies. The VelocImmune platform generates fully human monoclonal antibodies (hMAbs) to address clinically relevant targets of therapeutic interest. The VelocImmune mouse, unlike other hMAb mice, mounts a robust immune response that is virtually indistinguishable from that of a wild type mouse, resulting in a reliable and efficient platform for discovering fully human monoclonal antibodies.
Regeneron has developed and validated a suite of inter-related technology platforms - VelociGene®, VeliciMouse®, and VelocImmune -- that the Company believes can accelerate its therapeutic drug discovery programs and improve its ability to discover new hMAb product candidates through VelocImmune. These discovery platforms are designed to identify specific genes of therapeutic interest for a particular disease or cell type and validate targets through high-throughput production of mammalian models. VelociGene uses a proprietary process to create genetic modifications in a mouse in a precise and high-throughput manner and was recently selected by the National Institutes of Health for use in its Knockout Mouse Project. VelociGene allows Regeneron to produce mouse embryonic stem (ES) cells rapidly for elucidating the function of the altered genes. VelociMouse allows Regeneron scientists to generate mammalian models directly from ES cells without the need for chimeras or breeding. VelocImmune provides antibodies that address the targets identified in the mammalian models that can be developed as potential therapeutics.
About AstraZeneca
AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of $26.47 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4 Good Index.
About Cambridge Antibody Technology
Cambridge Antibody Technology (CAT) is a biopharmaceutical company using its capabilities and technologies in the discovery and development of new and innovative antibody medicines in selected therapeutic areas to bring improvements to seriously ill patients' lives. CAT is a leader in the discovery and development of human therapeutic antibodies and has an advanced proprietary platform technology for rapidly isolating human monoclonal antibodies using phage display and ribosome display systems. CAT has extensive phage antibody libraries, currently incorporating more than 100 billion distinct antibodies. These libraries form the basis for the Company's strategy to develop a portfolio of antibody-based drugs. CAT is part of the AstraZeneca group of companies. CAT employs around 300 people and is based near Cambridge, UK and in Palo Alto, USA. For more information: www.cambridgeantibody.com
About Regeneron Pharmaceuticals, Inc.
Regeneron is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders.
This news release discusses historical information and includes forward-looking statements about Regeneron and its products, programs, finances, and business, all of which involve a number of risks and uncertainties, such as risks associated with preclinical and clinical development of our drug candidates, determinations by regulatory and administrative governmental authorities which may delay or restrict our ability to continue to develop or commercialize our drug candidates, competing drugs that are superior to our product candidates, unanticipated expenses, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any collaboration agreement, including our agreements with the sanofi-aventis Group and Bayer HealthCare, to be canceled or to terminate without any product success, risks associated with third party intellectual property, and other material risks. A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission (SEC), including its Form 10-K for the year ended December 31, 2005 and Form 10-Q for the quarter ended September 30, 2006. Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise unless required by law.
Contact:
Regeneron Pharmaceuticals, Inc.
Media:
Lauren Tortorete, 212-845-5609
ltortorete@biosector2.com
or
Investor Relations:
Charles Poole, 914-345-7640
charles.poole@regeneron.com
http://biz.yahoo.com/bw/070205/20070205005429.html?.v=1
OT: LOL on Groß Sehr Gut!
Seattle Genetics this weeks winner! Up 26% in two days.
See news, company was apparently in NYC this week meeting with some investors.
http://finance.yahoo.com/q?s=sgen
Congrats to Thomas for further pointing out this birds nest on the ground (referring to SGEN's presentation and slides; I was impressed) when it was priced in the upper $6's and low $7's. David Miller has also been supporting this company for a while. Unfortunately I only picked up a small position before the big move. I am increasing my IDIX position a bit more on attractive pricing this week and Dew and dewophile's thougths regarding the VRTX quarterly call.
Rex thoughts earlier by ghmm
http://www.investorshub.com/boards/replies.asp?msg=16591286
And while you are speaking of football, hockey is also another sport where concussions are common. I won't even venture into boxing where the goal is to "knock out" your opponent!
2006 drug approvals: finding the niche
Joanna Owens
Companies move towards niche products to boost productivity.
Following a year of high-profile drug failures, it's not surprising that the number of 2006 FDA drug approvals has so far received a muted response. Analysts insist that research and development (R&D) productivity is 'steady' despite no significant increase in output, but lack of success with new medicines for broad disease indications seems to be leading companies to focus on expanding indications for existing drugs or on niche markets.
Only 18 new molecular entities (NMEs) — the same as in 2005 — and just 4 biologic license applications (BLAs) were approved in 2006 (Fig. 1; Table 1). The number of priority reviews and orphan designations compared with 2005 slipped slightly to ten and five, respectively (FIG. 2). The FDA has yet to confirm final numbers, but according to John Jenkins, Director of the FDA's Office of New Drugs, the decrease in approvals is a direct result of a reduced number of new drug applications (NDAs).
< see link below for full story with charts, etc.
http://www.nature.com/nrd/journal/v6/n2/full/nrd2247.html
Seattle Genetics (SGEN) up 13% (8.18) right now on heavy volume, breaking into new 52-week high.
OT: Very bizarre report on dog and his tongue in a paper schredder. Click on the video and look at the puppies tongue before the vet had to do a bunch of microstitching! Apparently this happens quite often to other pet owners who have a schredder and keep it on "automatic" setting.
http://abclocal.go.com/wtvg/story?section=local&id=4986527
OT: AP Fed Keeps Interest Rates at 5.25 Percent
Wednesday January 31, 2:19 pm ET
By Martin Crutsinger, AP Economics Writer
Federal Reserve Leaves Interest Rates Unchanged at 5.25 Percent for Fifth Consecutive Meeting
WASHINGTON (AP) -- The Federal Reserve, faced with a strongly rebounding economy, left interest rates unchanged on Wednesday while repeating concerns about inflation.
The central bank voted to leave the federal funds rate, the interest that banks charge each other, at 5.25 percent, where it has been since last June.
That decision had been widely expected given an economy that is exhibiting better-than-expected growth. While the Fed had been expected to start cutting rates later this year, economists are now worried that the central bank may feel the need to resume raising rates for fear that inflation pressures will not keep easing.
The rate action was supported by a unanimous 11-0 vote of the Federal Open Market Committee, the panel of Fed board members in Washington and regional bank presidents who meet eight times a year to set interest rates.
At the previous four meetings, Jeffrey Lacker, the president of the Richmond Fed regional bank, had dissented in favor of a further boost in rates. However, he is not a voting member of the FOMC this year.
The action means that banks' prime lending rate, the benchmark for millions of consumer and business loans, will remain unchanged at 8.25 percent.
http://biz.yahoo.com/ap/070131/fed_interest_rates.html?.v=10
RPRX-- yep, and rfj should be able to buy his last 25% easily with this volume at 13.76. I pick up a few more shares last week at 12.50. Rolled the dice a bit and got lucky.
RPRX trading at new 52-week high: 14.37 on higher volume.
All long holders are now "in the money". Heading into new uncharted high territory not seen in over 6 years. Shorts may be starting to pinch themselves.
http://finance.yahoo.com/q/bc?s=RPRX&t=my&l=on&z=m&q=l&c=
Good luck,
Spartex
As I had mentioned earlier, Schwab went from 30% to 50% margin requirement in my account after my RPRX had gone up 100%. I wonder if they put limitations on stocks that not only move down sharply, but up sharply, as was the case with RPRX.
Yes, I was using Yahoo as my link source to market wire and other news wires. I see that is a problem! :) Thanks for your update as well as caution.
Virexx Medical Corp. (REX)
From Yahoo MB:
Rex raising money (Not rated) 41 minutes ago Issuance of stock warrants for 15 million Canadian...will likely weigh on the stock until it prices...will close on March 15. Let's hope it's well received...
By the way, the interview with Biotech Monthly was upbeat. They've got intriguing platforms, and said their current bank balance would take them out about 13 months...so this financing should insure at least another year on top of that.
I'll cintinue to load up as the price declines
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_V/threadview?m=tm&bn=26969&tid=...
I find it interesting that this guy knows the news, as do others, and there still isn't a PR available. Is this usual for some of the Canadian companies in terms of getting their news out on US newswires?
Re: RPRX Dew is that true, you won't allow multiposts of RPRX here?
rfj is only interested in monitoring and replying on RPRX and other biotechs on this board. And the new RPRX board is getting limited interest.
tia for your reply.
Barron's list of biotech,pharmaceutical and medical companies that I gleaned from their IPO list of new stocks in 2006 (Jan 29, 2007 Barron's issue). Some of these may well be attractive shorting candidates in 2007. I'm just providing the symbols. Dew's got a few of these on his list. I'm not a proponent of shorting, but based on valuations in other biotechs which are further along in their trials with positive results and/or w/ approved drugs (RPRX, IDIX) many of these companies look poised for a fall, especially if the market has a 5% or so correction.
ACHN
ACOR
ALXA
ALTU
ARTE
BMTI
CADX
CPRX
CBLI
EBS
HNSN
NSTR
NOVC
OMPI
OMRI
OSIR
RDYN
REST
SGXP
THRM
TRBN
VLRX
VNDA
RPRX short interest up 517% for Jan!
January 2007 ShortInterest Percent Change Average DailyShare Volume Days to
Cover
RPRX Repros Therapeutics Inc. - Common Stock 313,608 (shares) 517.17 (% increase) 349,491 (avg daily vol, which sounds high) 1.00 (days to cover)
http://www.nasdaqtrader.com/asp/short_interest_resp.asp?searchby=Detail&IssueID=44033
Seems like those taking a short position are expecting a RPRX pull back in price. It is possible they may get hurt further, if not already. I'm curious what the avg. price is for this short position? I guess it would not be unusual to see some investors shorting RPRX after its 100% run since mid-Dec.
OT- Sponges
Well, even if synthetic, if the sponges are properly wet as the article says they will start to steam first. Eventually I think you may be right that the synthetic material could melt or break down.
I've been only nuking them for 25 seconds. The sponge is steaming and near boiling temps (hot!) which I consider sufficient to kill most household bacteria. I can't imagine going for longer than 1 minute, let along 10 min. Overkill imho.
RPRX
<I think it is reasonable--in terms of market cap--for this to be a $250-$350 M stock this year. However, in terms of multiples of current PPS, even this is an ambitious target.
With the stock offering (dilution), at the current price of around $13.2, the market cap will equal ~ 168 M.
According to your "reasonable" market cap for this year that would translate to a $19-27 dollar stock.
So are you saying $19-27 range is "an ambitious target" or are you talking more of a stock price in the $30++ range?
Regarding attending the event. If you had the spare time, I guess it would just be useful to see how their story is being communicated and the interest by the investors. Other than that, yeah, I understand your sentiment.
Thanks!
MPCPF: Are they even listed anymore? Last was on the pink sheets.
http://finance.yahoo.com/q?s=MPCPF.PK